Abstract:Jie Qian, 1, 2, * Xueyan Zhang, 2, * Bo Zhang, 2 Bo Yan, 2 Lin Wang, 3 Ping Gu, 2 Weimin Wang, 2 Huimin Wang, 2 Baohui Han 2 1 Department of Emergency Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 2 Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 3 Department of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China *These authors contributed equally to this work Correspondence: Baohui Han Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 # West Huaihai Road, Shanghai 230030, People's Republic of China Tel +86 21 62821990 ext.1421 Fax +86 21 32260806 Email 18930858216@163.com Purpose: Hepatic injury is a common side effect following tyrosine kinase inhibitor (TKI) therapy and our understanding usually comes from clinical trials. In this retrospective study, we aimed to investigate the characteristics, risk factors and regimen-related differences of epidermal growth factor receptor (EGFR)-TKI-related hepatic toxicity in patients with advanced lung adenocarcinoma (LAD). Patients and Methods: Liver function tests were documented in 424 patients admitted into the Shanghai Chest Hospital between January 2014 and December 2016 with advanced (IIIB/IV) LAD who received first-line gefitinib, erlotinib or icotinib. Hepatotoxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. The clinical spectrum and onset time of hepatic injury were evaluated. The risk factors of hepatic dysfunction were determined using a logistic regression analysis. Results: A total of 87 (20.5%) patients experienced hepatotoxicity and 5.7% were of grade 3/4 liver dysfunction. The median onset time of hepatotoxicity was 7 weeks. Presence of hepatitis virus (HR: 2.593, 95% CI: 1.090– 6.170, P=0.031) and pretreatment liver impairment (HR: 3.460, 95% CI: 1.746– 6.855, P< 0.001) were risk factors associated with increased risk of hepatotoxicity. Gefitinib (HR: 1.872, 95% CI: 1.028– 3.412, P=0.040) and erlotinib (HR: 3.578, 95% CI: 1.683– 7.609, P=0.001) had increased risk of hepatotoxicity compared to icotinib. Conclusion: The different toxic profile of EGFR-TKIs should be taken into account in the choice of treatment based on the patients' comorbidity. Keywords: lung adenocarcinoma, hepatotoxicity, tyrosine kinase inhibitor, gefitinib, erlotinib, icotinib

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

Osimertinib-induced severe bilateral pneumothorax: A case report

EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

EGFR-tyrosine Kinase Inhibitor Treatment in a Patient with Advanced Non-Small Cell Lung Cancer and Concurrent Exon 19 and 21 EGFR Mutations: A Case Report and Review of the Literature.

A Case Report of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors with T790M Mutation and Epithelial-to-mesenchymal Transition

Transformation to Small Cell Lung Cancer and Activation of KRAS During Long-Term Erlotinib Maintenance in a Patient with Non-Small Cell Lung Cancer: A Case Report

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review

Sequential small cell transformation and T790M mutation in an epidermal growth factor‐mutant lung adenocarcinoma: A rare occurrence with significant management implications

Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma

Resistance to Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in a Patient with Transformation from Lung Adenocarcinoma to Small Cell Lung Cancer: A Case Report

A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach

Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma

Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study

Fatal Interstitial Lung Disease Associated with a Series of Tyrosine Kinase Inhibitors Treatment in a Non-Small Cell Lung Cancer Patient: a Case Report

Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases

Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report